The role of micro RNAs let7c, 100 and 218 expression and their target RAS, C-MYC, BUB1, RB, SMARCA5, LAMB3 and Ki-67 in prostate cancer

Clinics

Volumn 68, Issue 5, 2013, Pages 652-657

  Reis, Sabrina T ^a   Timoszczuk, Luciana S ^a   Pontes Junior, José ^a   Viana, Nayara ^a   Silva, Iran A ^a   Dip, Nelson ^a   Srougi, Miguel ^a   Leite, Katia R M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

BUB1; C MYC; Immunohistochemistry; Ki 67; LAMB3; Micro RNA; Prognosis; Prostate Cancer; RAS; RB; SMARCA5; Tumor Markers

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BUB1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; KALININ; KI 67 ANTIGEN; MICRORNA; MIRN100 MICRORNA, HUMAN; MIRN218 MICRORNA, HUMAN; MIRNLET7 MICRORNA, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN; NONHISTONE PROTEIN; PROTEIN P21; PROTEIN SERINE THREONINE KINASE; RETINOBLASTOMA PROTEIN; SMARCA5 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; ARTICLE; BONE TUMOR; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROSTATE TUMOR;

ADENOSINE TRIPHOSPHATASES; ADULT; BONE NEOPLASMS; CELL ADHESION MOLECULES; CHROMOSOMAL PROTEINS, NON-HISTONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS P21(RAS); RETINOBLASTOMA PROTEIN;

EID: 84878430826     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(05)12     Document Type: Article

References (30)

1. Siegel R, Desantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-41, http://dx.doi.org/10.3322/caac.21149.
2. Whitmore WJ Jr. Natural history and staging of prostate cancer. Urol Clin North Am. 1984;11(2):205-20.
3. Leite KR, Sousa-Canavez JM, Reis ST, Tomiyama AH, Camara-Lopes LH, Sañudo A, et al. Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. 2011;29(3):265-9.
4. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120(5):635-47, http://dx.doi.org/10.1016/j.cell.2005.01.014.
5. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, et al. MicroRNA let-7a downregulates C-MYC and reverts C-MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 2007;67(20):9762-70, http://dx.doi.org/10.1158/0008-5472.CAN-07-2462.
6. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA. Khan Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene. 2008;27(18):2575-82, http://dx.doi.org/10.1038/sj.onc.1210919.
7. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with C-MYC. Science. 1991;251(4998):1211-7, http://dx.doi.org/10.1126/science.2006 410.
8. Stopka T, Skoultchi AI. The ISWI ATPase Snf2h is required for early mouse development. PNAS. 2003;100(24):14097-102, http://dx.doi.org/ 10.1073/pnas.2336105100.
9. BaRBacid M: RAS genes. Annu Rev Biochem 56:779-827, 1987. http://dx. doi.org/10.1146/annurev.bi.56.070187.004023.
10. Adams PD, Kaelin WG Jr. Negative control elements of the cell cycle in human tumors. Curr Opin Cell Biol. 1998;10(6):791-7, http://dx.doi.org/ 10.1016/S0955-0674(98)80123-3.
11. Bullwinkel J, Baron-Lühr B, Lüdemann A, Wohlenberg C, Gerdes J, Scholzen T. Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferatingcells. J Cell Physiol. 2006;206(3):624-35, http://dx.doi.org/10.1002/jcp.20494.
12. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524-9, http://dx.doi.org/10.1073/pnas. 242606799.
13. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERe) and represses ERe messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol. 2007;21(5):1132-47, http://dx.doi.org/10.1210/me.2007-0022.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2deltadeltaCT method. Methods. 2001;25(4):402-8, http://dx.doi.org/10.1006/meth.2001.1262.
15. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133(4):1710-5.
16. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology. 1990;17(6):489-503, http://dx.doi.org/10. 1111/j.1365-2559.1990.tb00788.x.
17. Cher ML, Chew K, Rosenau W, Carroll PR. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate. 1995;26(2):87-93, http://dx.doi. org/10.1002/pros.2990260205.
18. Gallee MPW, Visser-de Jong E, ten Kate FWJ, Schroeder FH, van der Kwast TH. Monoclonal antibody Ki-67 DEFINED Growth fraction in benign prostatic hyperplasia and prostatic cancer. J Urol. 1989; 142(5):1342-6.
19. Raymond WA, Leong ASY, Bolt JW, Milios J, Jose JS. Growth fractions in human prostatic carcinoma determined by the Ki-67 immunostaining. J Pathol. 1988;156(2):161-7, http://dx.doi.org/10.1002/path.1711560211.
20. McLoughlin J, Foster CS, Price P, Williams G, Abel PD. Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Br J Urol. 1993;72(1):92-7.
21. Sadi MV, Barrack ER. Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer. 1991;67(12):3065-71, http://dx.doi.org/10.1002/1097-0142(19910615)67:12,3065::AID-CN CR2820671222.3.0.CO;2-U.
22. Van Weerden WM, Moerings EP, van Kreuningen A, de Jong FH, van Steenbrugge GJ, Schröder FH. Ki-67 expression and BrdUrd incorporation as markers of proliferative activity in human prostate tumour models. Cell Prolif. 1993;26(1):67-75, http://dx.doi.org/10.1111/j.1365-2184.1993.tb00007.x.
23. BaRBacid M: RAS genes. Annu Rev Biochem. 1987;56:779-827.
24. Zachos G, Spandidos DA. Expression of RASproto-oncogenes: regulation and implications in the development of human tumors. Crit Rev Oncol Hematol. 1997;26(2):65-75, http://dx.doi.org/10.1016/S1040-8428(97) 00013-9.
25. Lim KH, Counter CM. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell. 2005;8(5):381-92, http://dx.doi.org/10.1016/j.ccr.2005.10.014.
26. Ambrosch P, Schlott T, Hilmes D, Ruschenburg I. p16 alterations and retinoblastoma protein expression in squamous cell carcinoma and neighboring dysplasia from the upper aerodigestive tract. Virchows Arch. 2001;438(4):343-9, http://dx.doi.org/10.1007/s004280000368.
27. Maddison LA, Sutherland BW, Barrios RJ, Greenberg NM. Conditional deletion of RB causes early stage prostate cancer. Cancer Res. 2004;64(17):6018-25, http://dx.doi.org/10.1158/0008-5472.CAN-03-2509.
28. Hao J, Yang Y, McDaniel KM, Dalkin BL, Cress AE, Nagle RB. Differential expression of laminin 5 (alpha 3 beta 3 gamma 2) by human malignant and normal prostate. Am J Pathol. 1996;149(4):1341-9.
29. Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol. 2003;200(4):423-8, http://dx.doi.org/10. 1002/path.1437.
30. Nagle RB. Role of the extracellular matrix in prostate carcinogenesis. J Cell Biochem. 2004;91(1):36-40, http://dx.doi.org/10.1002/jcb.10692.